Lack Of Harmonization In ICH Q12 Draft Guideline Draws Fire In US
Executive Summary
Major pharmaceutical industry groups in the US, like their counterparts in the EU, are concerned that the draft ICH Q12 guideline does not align with the established legal framework in certain ICH regions, including the EU, in terms of implementing key concepts such as established conditions and product lifecycle management.
You may also be interested in...
EU Sees Snags In Implementing ICH Guide On Post-Approval Changes
EU authorities say the new tools and concepts needed for implementing the new international guideline on post-approval changes (ICH Q12) will be considered when the EU framework is reviewed.
Removal Of ‘Legal’ And ‘Implicit’ Terms Cleared Way For ICH Q12 Guideline
Concerns about potential regional variation and ambiguous applicability subside with final revision of lifecycle management guideline; training preparations begin.
Differences Put Aside As ICH Finalizes Guide On Post Approval Changes
An international guideline on managing post approval changes to drugs, which was initially criticized because of its incompatibility with legal frameworks in certain ICH regions such as the EU, has been finalized.